BUZZ-Tempus AI rises after securing FDA approval for tumor test

Tempus Al

Tempus Al

TEM

0.00

** Shares of AI-enabled precision medicine firm Tempus AI TEM.O rise 7.2% to $55.07 premarket

** Co says U.S. FDA approved its diagnostic tool, xT CDx, for genetic profiling of solid tumors to help doctors identify which therapies will work best for the patient

** The test is designed to detect genetic alterations without requiring a matching normal saliva or blood sample from the patient

** xT CDx is also approved as a companion diagnostic tool to identify colorectal cancer patients who may benefit from targeted therapies

** Up to last close, stock down 13.1% YTD


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.